Promethera Biosciences Announces First-Dosing in Phase 2a Clinical Study Evaluating World’s First Liver Stem Cell Therapy in Late-Stage NASH Patients

68

MONT-SAINT-GUIBERT, Belgium & TOKYO–(BUSINESS WIRE)–Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced the dosing of a first patient in a Phase 2a clinical study for the company’s HepaStem development program in patients with late stage non-alcoholic steatohepatitis (NASH). The multicenter, open-label PANASH study will evaluate the safety and preliminary efficacy of Promethera’s investigational drug HepaStem, a novel allogenic cell-based http://www.businesswire.com/news/home/20190509005173/en/Promethera-Biosciences-Announces-First-Dosing-Phase-2a-Clinical/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==

- Advertisement -